REGN Regeneron Pharmaceuticals
- 883.200
- -7.480-0.84%
- 881.210
- -1.990-0.23%
Regeneron Pharmaceuticals News
Apple and Amazon Earnings, the Fed, Jobs Data, and More to Watch
Earnings season gets busy. Plus, the Federal Reserve is expected to hold interest rates steady and jobs growth is expected to decelerate in April.
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says
Regeneron Pharmaceuticals (REGN) is expected to grapple with Q1 seasonality when reporting March quarter results early next month, despite the ongoing Eylea HD launch, Oppenheimer said in a note Thurs
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,189, according to analysts polled by Capital IQ. Price: 885.00, Change: -5.68, Percent Ch
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting dos
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma -- WSJ
By David Wainer Bristol-Myers Squibbs market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnin
Regeneron (REGN) Reports Next Week: What You Should Expect
UPDATE 1-AbbVie's Skin Disease Drug Found to Be More Effective Than Regeneron's Dupixent in Study
Express News | Regeneron Pharmaceuticals Inc - Mammoth Eligible to Receive Royalty Rates Ranging From Single Digits to Mid-Teens on Future Net Sales of Products
Express News | Regeneron Pharmaceuticals Inc - Mammoth Is Eligible to Receive up to $370 Mln per Target in Development, Regulatory and Commercial Milestone Payments
Express News | Regeneron Pharmaceuticals Inc - Mammoth to Receive $100 Mln Total Upfront Payment and Equity Investment From Regeneron at Signing
Express News | Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)
Express News | Sanofi - Expects 2024 Business EPS to Remain Roughly Stable Excluding Impact of Expected Effective Tax Rate Increase to 21%
Express News | Sanofi - Q1 Business Net Income EUR 2.22 Bln Vs EUR 2.17 Bln in Vara Research Consensus
Express News | Sanofi - Reaffirms Financial Guidance for 2024
Express News | Sanofi - Expects 2024 Business EPS to Decrease Low Single-Digit at Cer Including Higher Expected Tax Rate
Express News | Sanofi - Q1 Published Net Sales Ifrs EUR 10.46 Bln Vs EUR 10.26 Bln in Vara Research Consensus
Express News | Sanofi - Applying Average April 2024 Exchange Rates, Currency Impact on 2024 Business EPS Is Estimated Between -5.5% to -6.5%
Express News | Sanofi - Reaffirms Increasing Pipeline News Flow Over 2024-2025, Including 12 Phase 3 Data Readouts
Express News | Sanofi - Q1 2024 Free Cash Flow Before Restructuring, Acquisitions and Disposals Amounted to -EUR 78 Mln
Analysis
Price Target
No Data
